Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Discovery Corporation, or HDC, has entered into an agreement with Abbott to commercialize HDC's new molecular diagnostics gene-based tests for clinically significant prostate cancer.
Subscribe to our email newsletter
Abbott has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC’s tissue-based prostate cancer test as well as HDC’s urine-based prostate cancer test.
Stephen Barnhill, chairman and CEO of HDC, said: “We are very pleased to partner with Abbott on commercialization of these exciting new molecular diagnostic tests for prostate cancer. Abbott is an innovative leader in the fast paced, high growth medical technology space serving customers around the world.”